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Abstract A peptide from the C-terminal domain of thrombo-
spondin-1 (4N1-1) has been proposed to stimulate platelet ag-
gregation by a novel mechanism involving both an activation-
independent agglutination and an activation-dependent, glyco-
protein (GP) IIb/IIIa-mediated aggregation which involves
GPVI signaling but does not involve CD47. The present study
demonstrates that 4N1-1 stimulated a di¡erent pattern of signal
transduction pathways than the GPVI agonist convulxin. Fur-
thermore, 4N1-1-induced platelet aggregation was activation-in-
dependent and not dependent on GPVI or GPIIb/IIIa. Interest-
ingly, 4N1-1 also stimulated activation-independent agglutina-
tion of di¡erent megakaryocytic and non-megakaryocytic cells.
4N1-1-induced cell agglutination but not platelet signaling was
inhibited by anti-CD47 antibodies.
, 2003 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Thrombospondin-1 is a multidomain glycoprotein, which is
stored in the K-granules of platelets [1]. Upon platelet activa-
tion it becomes secreted and binds to the cell surface where it
contributes to the stabilization of platelet aggregates [2]. 4N1-
1 (H-Arg-Phe-Tyr-Val-Val-Met-Trp-Lys-OH) is a peptide
from the C-terminal cell binding domain of thrombospon-
din-1. In contrast to the full-length protein, 4N1-1 was re-
ported to induce di¡erent signaling events. On immobilized
matrices it was shown to cause platelet spreading and aggre-
gation in a tyrosine kinase-, phosphatidylinositol 3-kinase-
and protein kinase C-dependent fashion [3^5]. The receptor
mediating these e¡ects appears to be the integrin-associated
protein CD47, since a direct binding for 4N1-1 could be dem-
onstrated [3] and 4N1-1-induced platelet aggregation on im-
mobilized collagen was abolished in CD473/3 mice [5]. These
data collectively suggested that CD47 mediates the activating
e¡ects of 4N1-1 on platelets adhering to immobilized matri-
ces.
However, a recent study has demonstrated that 4N1-1-in-
duced aggregation of stirred platelets occurred in CD473/3
mice [6]. In addition, 4N1-1 has been proposed to induce both
an activation-independent platelet agglutination and an acti-
vation-dependent, glycoprotein (GP) IIb/IIIa-mediated plate-
let aggregation. 4N1-1 stimulated a rapid tyrosine phospho-
rylation of the FcRQ chain, Syk, SLP-76, and phospholipase
CQ2, thus indicating that 4N1-1 signals through a pathway
similar to that of GPVI agonists, such as convulxin [7,8]. In
addition, the phosphorylated FcRQ chain in platelets stimu-
lated with 4N1-1 was shown to coimmunoprecipitate with
GPVI. However, it is not clear if GPVI is directly activated
by 4N1-1 in platelets. Thus, there is controversy about the
mechanisms of 4N1-1-induced platelet aggregation.
The present study investigated the e¡ects of 4N1-1 as com-
pared to thrombin and convulxin on several signaling path-
ways and the e¡ects of platelet inhibitors on 4N1-1-induced
platelet aggregation. We demonstrate that 4N1-1 stimulates
distinct signaling pathways in platelets di¡erent from those
induced by the GPVI-speci¢c agonist convulxin and that
4N1-1-induced aggregation is not altered in GPVI-de¢cient
mouse platelets. Furthermore, we show that 4N1-1-induced
aggregation occurs entirely independently of GPIIb/IIIa re-
ceptors, is not cell type-speci¢c, and is not dependent on cel-
lular activation. CD47 may mediate cell agglutination induced
by 4N1-1.
2. Materials and methods
2.1. Materials
H-Arg-Phe-Tyr-Val-Val-Met-Trp-Lys-OH (4N1-1) was from Bach-
em Biochemica (Heidelberg, Germany). Phospho-speci¢c antibodies
against Akt (Ser473 and Thr308), p38 mitogen-activated protein
(MAP) kinase and extracellular signal-regulated kinases (ERK)-1
and 2 were from Cell Signaling Technology (Beverly, MA, USA).
Anti-CD47 antibodies (clone B6H12) were from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA). Fluorescein isothiocyanate-conju-
gated antibodies against CD62P were from Coulter Immunotech
(Marseille, France). PP2 was from Calbiochem-Novabiochem (San
Diego, CA, USA). Iloprost was from Schering (Berlin, Germany).
Abciximab was from Centocor (Leiden, The Netherlands). Epti¢ba-
tide was from Essex Pharma (Munich, Germany). Tiro¢ban was from
Merck Sharp and Dohme (Haar, Germany). Oregon-Green ¢brinogen
was from Molecular Probes (Eugene, OR, USA). Convulxin was from
Pentapharm (Basel, Switzerland). K-Thrombin was a gift from Dr.
Stu«rzebecher (Erfurt, Germany). All other chemicals were from Sigma
(Deisenhofen, Germany).
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2.2. Preparation of washed platelets and measurement of platelet
aggregation and cell agglutination
Platelet-rich plasma was prepared from bu¡y coats by centrifuga-
tion at 250Ug and room temperature for 10 min. Platelets were
washed as previously described [9] and were resuspended in HEPES-
bu¡ered Tyrode bu¡er (pH 7.4) containing 2 mM Ca2þ. Platelet ag-
gregation was measured turbidimetrically as previously described [10].
Aggregation values are given as the maximum change in light trans-
mittance (100% was the di¡erence between washed platelets and bu¡-
er). In some experiments, the e¡ects of 4N1-1 on GPVI-depleted
mouse platelets was studied as described previously [11]. Agglutina-
tion of erythrocytes and cultured cells was also measured turbidimetri-
cally as described above. Erythrocyte agglutination was also evaluated
macroscopically.
2.3. Measurement of [Ca2+]i
Platelet-rich plasma was loaded with fura-2/AM (5 WM) for 30 min
at 37‡C. Thereafter, platelets were isolated [12] and £uorescence was
measured spectro£uorophotometrically (RF-5000, Shimadzu, Kyoto,
Japan) at an excitation wavelength of 340 nm and an emission wave-
length of 500 nm.
2.4. Western blotting
Platelets were lysed in 2U lysis bu¡er (1U : 62.5 mM Tris^HCl, pH
6.8, 10% glycerol, 2% w/v sodium dodecyl sulfate (SDS), 0.1% w/v
bromophenol blue). Proteins were resolved by SDS^polyacrylamide
(10%) gel electrophoresis, blotted and probed with antibodies as pre-
viously described [13]. Densitometric analysis was performed using a
calibrated scanner densitometer (GS-800, Bio-Rad, Munich, Ger-
many).
2.5. Flow cytometry
Expression of CD62P was measured as previously described [12].
2.6. Cell culture
Human venous and arterial smooth muscle cells were isolated by
explant technique [14]. The cell lines MEG-01, CMK and U937 were
obtained from the German Collection of Microorganisms and Cell
Cultures and cultured as described [13].
2.7. Statistics
Data are meanPS.E.M. of n independent experiments. Statistical
analysis was performed by one-way analysis of variance followed by
Bonferroni multiple comparisons test using GraphPad InStat version
3.01 for Windows 95 (GraphPad Software, San Diego, CA, USA).
P levels of 6 0.05 were considered signi¢cant.
3. Results
3.1. E¡ects of 4N1-1 on platelet aggregation
4N1-1 concentration-dependently induced platelet aggrega-
tion (Fig. 1a). However, while 100 WM 4N1-1 consistently
stimulated platelet aggregation in each sample studied, the
e¡ects of lower concentrations of 4N1-1 were variable [3].
Platelet agglutination, amounting to about 25% of the aggre-
gation amplitude in native platelets, was also observed in
paraformaldehyde-¢xed platelets (Fig. 1b,c).
3.2. E¡ects of 4N1-1 on platelet signaling
4N1-1-induced aggregation was accompanied by increases
in [Ca2þ]i with maximum values comparable to those induced
by thrombin (0.1 U/ml). However, while the increases in
[Ca2þ]i were very rapid upon stimulation with thrombin,
peak increases in [Ca2þ]i in 4N1-1-stimulated platelets oc-
curred after about 2 min (Fig. 2). 4N1-1 (100 WM) stimulated
a time-dependent phosphorylation of Akt at Ser407 (Fig. 3a)
and Thr308 (not shown) with a time course similar to that
induced by convulxin (Fig. 3b). Akt phosphorylation induced
by either stimulus was completely inhibited by the Src family
tyrosine kinase inhibitor PP2 (10 WM) (Fig. 3c). Similar to
convulxin (Fig. 3e), 4N1-1 (100 WM) also stimulated a time-
dependent phosphorylation of p38 MAP kinase (Fig. 3d).
Again, p38 MAP kinase phosphorylation induced by either
stimulus was completely inhibited by PP2 (10 WM) (Fig. 3f).
Interestingly, 4N1-1 did not stimulate ERK-1/2 phosphoryla-
tion (Fig. 3g), while thrombin or convulxin did (Fig. 3h).
3.3. E¡ects of 4N1-1 on aggregation of GPVI-de¢cient
platelets
Together, the above described experiments demonstrated
that 4N1-1 induces a di¡erent pattern of signal transduction
pathways than the GPVI-speci¢c agonist, convulxin. There-
fore, the proposed involvement of GPVI signaling in 4N1-1-
induced aggregation was tested directly in GPVI-de¢cient
mouse platelets [11]. Strikingly, 4N1-1-induced aggregation
was not altered in GPVI-de¢cient platelets clearly excluding
an essential role of GPVI in this process (Fig. 4).
Fig. 1. E¡ects of 4N1-1 on aggregation of native and paraformalde-
hyde (PFA, 1%)-¢xed platelets. a: Original tracings, demonstrating
a concentration-dependent e¡ect of 4N1-1. b: Original tracings dem-
onstrating the e¡ects of 4N1-1 on aggregation of native as com-
pared to PFA-¢xed platelets. c: Quantitative comparison of the ef-
fects of 4N1-1 on aggregation of native (closed bar) as compared to
PFA-¢xed platelets (open bar) (meansPS.E.M., n=6).
Fig. 2. Original tracings, demonstrating the e¡ects of 4N1-1 (100
WM) as compared to thrombin (1 U/ml) on [Ca2þ]i. Similar results
were obtained in three independent experiments.
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3.4. 4N1-1-induced aggregation is not altered by GPIIb/IIIa
inhibitors
In contrast to the previously published data [6], 4N1-1-in-
duced platelet aggregation was not a¡ected by high concen-
trations of di¡erent GPIIb/IIIa inhibitors (10 WM abciximab,
a monoclonal antibody fragment; 3 WM epti¢batide, a cyclic
peptide; 100 nM tiro¢ban, a peptide mimetic; 500 WM
RGDS) (Fig. 5). In contrast, all inhibitors reduced 0.1 U/ml
thrombin-induced aggregation by about 80% and completely
blocked aggregation in response to 100 ng/ml convulxin (not
shown). Together, these data demonstrate that 4N1-1-induced
platelet aggregation is an entirely GPIIb/IIIa-independent
process.
3.5. E¡ects of platelet function inhibitors on 4N1-1-induced
platelet aggregation
The surprising ¢nding that neither GPVI nor GPIIb/IIIa is
Fig. 3. E¡ects of 4N1-1 (100 WM) as compared to convulxin (CVX, 100 ng/ml) or thrombin (1 U/ml, 5 min) on phosphorylation of Akt (a,b),
p38 MAP kinase (d,e), and ERK-1/2 (g,h). c,f : The e¡ects of the Src family tyrosine inhibitor PP2 (10 WM). a,d,g: Representative Western
blots and the densitometric analysis (meansPS.E.M.) of n=5 experiments.
Fig. 4. Original tracings, demonstrating the aggregatory e¡ects of
4N1-1 (250 WM) on platelets isolated from wild type mice and from
GPVI-depleted mice. Similar results were obtained in three indepen-
dent experiments.
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critically involved in 4N1-1-induced platelet aggregation
prompted us to test the functional signi¢cance of signaling
pathways activated by this agonist. For this purpose, platelets
were pre-incubated with the cell-permeable Ca2þ chelator
BAPTA/AM (100 WM), the phosphoinositide 3-kinase inhib-
itors wortmannin (300 nM) or LY-294002 (100 WM), or the
p38 MAP kinase inhibitors SB202190 (10^100 WM) or
SB203880 (10^100 WM) for 15 min and then stimulated with
4N1-1. Interestingly, none of these inhibitors altered the ag-
gregation response (data not shown). Furthermore, 4N1-1-in-
duced platelet aggregation was not a¡ected by the cAMP-
elevating agents iloprost (100 nM) or prostaglandin E1 (300
nM) (not shown), or the cGMP-elevating agent sodium nitro-
prusside (SNP, 100 WM) (Fig. 6a,b). In contrast, platelet ag-
gregation induced by thrombin (0.1 U/ml) (Fig. 6a,b) or con-
vulxin (data not shown) was almost completely inhibited by
iloprost or SNP. Interestingly, the activation of signal trans-
duction pathways by 4N1-1, as exempli¢ed by p38 MAP ki-
nase phosphorylation, was almost completely inhibited by ilo-
prost (Fig. 6c). Similarly, although platelet aggregation was
not a¡ected, iloprost markedly (about 50%) inhibited platelet
K-granule secretion (CD62P expression, Fig. 6d). Thus, inhi-
bition of some platelet function aspects (p38 MAP kinase
phosphorylation, K-granule secretion) by iloprost did not re-
sult in any inhibition of 4N1-1-induced platelet aggregation.
3.6. 4N1-1-induced agglutination is not cell type-speci¢c but is
mediated by CD47
The results of the above described experiments clearly in-
dicate that 4N1-1 might aggregate platelets independently of
classical platelet receptors/signaling pathways. To test this hy-
pothesis directly, the e¡ects of 4N1-1 were tested on di¡erent
megakaryocytic and non-megakaryocytic cells. As shown in
Fig. 7a,b, 4N1-1 stimulated agglutination of two promegakar-
yocytic cell lines CMK and MEG-01 whereas no such e¡ect
was seen with convulxin (Fig. 7a,b) or thrombin (not shown).
Interestingly, 4N1-1 induced p38 MAP kinase phosphoryla-
Fig. 5. E¡ects of various GPIIb/IIIa inhibitors on 100 WM 4N1-1-
and 0.1 U/ml thrombin-induced platelet aggregation. a: Original
tracings, demonstrating the e¡ects of abciximab (10 Wg/ml).
b: Quantitative analysis of the e¡ects of abciximab (10 Wg/ml), epti-
¢batide (3 WM), tiro¢ban (100 nM), and RGDS (500 WM) (means
PS.E.M., n=5, *P6 0.05 versus control).
Fig. 6. E¡ects of iloprost (100 nM) and SNP (100 WM) on 100 WM 4N1-1-induced platelet aggregation (a,b), p38 MAP kinase phosphorylation
(c), and K-granule secretion (CD62P expression) (d). In a,b, the e¡ects of iloprost on 0.1 U/ml thrombin-induced platelet aggregation are shown
for comparison (meansPS.E.M., n=5, *P6 0.05 vs. control).
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tion in MEG-01 but not in CMK cells (Fig. 7c,d), further
indicating an activation-independent agglutinatory e¡ects of
the peptide. This was con¢rmed by the observation that
4N1-1 also stimulated agglutination of non-megakaryocytic
cells, including erythrocytes (Fig. 6e), arterial and venous
smooth muscle cells, and the monocytic U937 cells (not
shown). In contrast to the previously published data with
CD473/3 mice [6], 4N1-1-induced aggregation of platelets
(Fig. 8a) and agglutination of erythrocytes (Fig. 8b) was com-
pletely blocked by neutralizing anti-CD47 antibodies. How-
ever, these antibodies did not inhibit 4N1-1-induced platelet
signaling (p38 MAP kinase phosphorylation) (Fig. 8c).
4. Discussion
The present study investigated the e¡ects of 4N1-1 on sev-
eral signaling pathways and the e¡ects of di¡erent speci¢c
platelet inhibitors on 4N1-1-induced platelet aggregation.
4N1-1 has recently been proposed to signal through a path-
way similar to that used by the collagen receptor GPVI [6] as
the peptide induced tyrosine phosphorylation of the FcRQ
chain, Syk, SLP-76 and phospholipase CQ2. In addition, the
phosphorylated FcRQ chain was shown to coprecipitate with
GPVI. Although there is indirect evidence in non-platelet cells
that the GPVI/FcRQ chain is not activated by 4N1-1 [6], sug-
gesting that 4N1-1 does not directly activate GPVI in plate-
lets, this issue has not yet been experimentally addressed.
However, although 4N1-1 stimulated several platelet signaling
events in a tyrosine kinase-dependent fashion, a di¡erent pat-
tern of signal transduction pathways was observed upon stim-
ulation with 4N1-1, as compared to the GPVI-speci¢c agonist
convulxin. For example, 4N1-1 did not stimulate ERK-1/2
phosphorylation, while convulxin did. In addition, using
GPVI-de¢cient mouse platelets, the present study excludes a
role of GPVI in 4N1-1-induced platelet aggregation.
In contrast to previous ¢ndings, where at least a partial
inhibition of 4N1-1-induced aggregation by RGDS peptide
was reported [6], no inhibitory e¡ects of several GPIIb/IIIa
inhibitors, including abciximab, tiro¢ban, epti¢batide, and
RGDS, were observed in the present study. It may be di⁄cult
to explain these discrepancies at present but it is clear that the
concentrations used in the current study were high enough to
completely block surface GPIIb/IIIa receptors [15]. Accord-
ingly, thrombin-induced platelet aggregation was inhibited
by about 80% under these conditions. The residual platelet
aggregation in the presence of GPIIb/IIIa inhibitors can be
explained by the rapid ¢brinogen binding kinetics to external-
ized GPIIb/IIIa receptors [12,16]. Similarly, convulxin-induced
platelet aggregation was completely inhibited by GPIIb/IIIa
inhibitors, thus indicating a further di¡erence between 4N1-1-
and convulxin/GPVI-mediated platelet aggregation.
The unexpected ¢nding that 4N1-1-induced platelet aggre-
gation occurred entirely independently of GPIIb/IIIa strongly
suggested that classical platelet signaling pathways may not be
critically involved in this process. This hypothesis was
strongly con¢rmed by studies using speci¢c inhibitors demon-
strating that increases in [Ca2þ]i, phosphorylation of Akt and
p38 MAP kinase are not required for 4N1-1-induced platelet
aggregation.
Furthermore, although 4N1-1-induced signaling (p38 MAP
kinase phosphorylation), GPIIb/IIIa receptor activation (¢-
brinogen binding), and K-granule secretion (CD62P expres-
sion) were markedly inhibited by the prostacyclin mimetic
iloprost, platelet aggregation was not a¡ected at all. Similar
¢ndings were obtained with SNP. This was a striking and
Fig. 7. E¡ects of 4N1-1 as compared to convulxin (CVX, 100 ng/
ml) on agglutination of the megakaryocytic cell lines CMK (a) and
MEG-01 (b), and erythrocytes (e). The e¡ects of 4N1-1 and convul-
xin on p38 MAP kinase phosphorylation are shown in c,d. Similar
results were obtained in two independent experiments.
Fig. 8. E¡ects of neutralizing anti-CD47 antibodies (30 Wg/ml) on
platelet aggregation (a) and erythrocyte agglutination (b). The ef-
fects of neutralizing anti-CD47 antibodies on 4N1-1-induced p38
MAP kinase phosphorylation are shown in c. Similar results were
obtained in two independent experiments.
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unexpected ¢nding, because elevation of either intracellular
cAMP or cGMP concentrations is the most potent endoge-
nous mechanism of platelet inhibition [17]. Although cAMP-
insensitive signaling pathways in platelets, especially those
mediated by GPVI, have been described [18^21], platelet ag-
gregation induced by any known agonist, including GPVI
activators, can be inhibited by elevation of cyclic nucleotides
[17,22]. In agreement with this, platelet aggregation induced
by convulxin or by thrombin, which is the strongest known
platelet stimulus, was almost completely blocked by iloprost
or by SNP.
Together, these observations demonstrate that 4N1-1 stim-
ulates platelet aggregation in a GPVI- and GPIIb/IIIa-inde-
pendent fashion. On the other hand, GPIbK has previously
been shown to be not involved [6]. Furthermore, inhibition of
K2 integrins has no e¡ect on 4N1-1-induced aggregation of
mouse platelets platelet (Aktas and Nieswandt, unpublished
observation). Finally, neither the inhibition of any signaling
pathway induced by 4N1-1 nor the inhibition of platelet acti-
vation by elevation of cyclic nucleotides had an e¡ect on 4N1-
1-induced aggregation, strongly suggesting that 4N1-1 might
aggregate platelets independently of classical platelet recep-
tors/signaling pathways. This was con¢rmed by the ¢nding
that 4N1-1 stimulated agglutination of two promegakaryo-
cytic cell lines (CMK and MEG-01) and non-megakaryocytic
cells, including erythrocytes, arterial and venous smooth
muscle cells and the monocytic cell line U937. Interestingly,
4N1-1 stimulated p38 MAP kinase phosphorylation in MEG-
01 but not in CMK cells, further indicating that stimulation of
intracellular signaling events, such as p38 MAP kinase phos-
phorylation, might not be required for the e¡ects on cell ag-
glutination. Furthermore, experiments with neutralizing anti-
bodies strongly suggest that CD47 might mediate the
agglutinating e¡ects of 4N1-1. This is in contrast to data
obtained with CD43/3 mice [6]. On the other hand, 4N1-1-
induced platelet aggregation on immobilized collagen was
completely abolished in CD473/3 mice [5] and a direct bind-
ing of 4N1-1 to CD47 could be demonstrated [3]. In addition,
in the study by Tulasne et al. [6], F(abP)2 fragment of anti-
CD47 antibodies did not inhibit 4N1-1-induced platelet aggre-
gation. However, in previous studies this antibody was shown
to block 4N1-1-induced spreading of platelets on immobilized
¢brinogen [4]. One possible explanation for these divergent
¢ndings may be the fact, that in our study, as well as in the
study by Chung et al. [4], the whole antibody (also B6H12)
was used.
Interestingly, neutralizing anti-CD47 antibodies did not in-
hibit 4N1-1-induced p38 MAP kinase phosphorylation in
platelets, indicating that 4N1-1 might also bind to receptors
other than CD47.
It is concluded that 4N1-1 stimulates aggregation of plate-
lets by an activation-independent mechanism which does not
involve GPVI signaling. 4N1-1-induced aggregation is not de-
pendent on GPIIb/IIIa receptors and also occurs in non-
megakaryocytic cells. CD47 may mediate cell agglutination
induced by 4N1-1.
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